Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Heartburn

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    72 result(s) found for: Heartburn. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2016-000994-19 Sponsor Protocol Number: GER/026115 Start Date*: 2016-07-08
    Sponsor Name:Gerolsteiner Brunnen GmbH & Co. KG
    Full Title: Doubleblind, randomised, placebo-controlled clinical trial to evaluate the safety and efficacy of Gerolsteiner Heilwasser in NERD patients with heartburn
    Medical condition: functional dyspeptic complaints, particularly heartburn (at least 3 months prior to study start, on at least 4 days per week)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004856 10019326 Heartburn LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001100-30 Sponsor Protocol Number: 1334hew16ct Start Date*: 2018-10-24
    Sponsor Name:Fachingen Heil- und Mineralbrunnen GmbH
    Full Title: Investigation of efficacy and tolerability of the healing water Staatl. Fachingen STILL in patients for symptomatic treatment of heartburn in comparison to placebo
    Medical condition: Efficacy and tolerability investigations of a healing water in symptomatic treatment of heartburn
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10019326 Heartburn LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003739-40 Sponsor Protocol Number: 59153 Start Date*: 2017-03-06
    Sponsor Name:AMC Amsterdam
    Full Title: The effect of Iberogast on heartburn in patients with dyspepsia
    Medical condition: Dyspepsia (according to the Rome III criteria) with heartburn. Upper gastro-intestinal causes of the complaints excluded via gastroscopy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001584-22 Sponsor Protocol Number: VDM/032711 Start Date*: 2013-09-16
    Sponsor Name:Gerolsteiner Brunnen GmbH & Co. KG
    Full Title: Pilot study with St. Gero for heartburn
    Medical condition: Functional dyspeptic complaints, particularly heartburn (at least 3 months prior to study start, at least twice per week)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004856 10019326 Heartburn LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001256-36 Sponsor Protocol Number: FACH/023212 Start Date*: 2013-06-14
    Sponsor Name:Fachingen Heil- und Mineralbrunnen GmbH
    Full Title: Pilot study with Staatl. Fachingen STILL for functional dyspepsia (particularly heartburn)
    Medical condition: Functional dyspeptic complaints, particularly heartburn (at least 3 months prior to study start, at least twice per week)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004856 10019326 Heartburn LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019414-24 Sponsor Protocol Number: GA0921 Start Date*: 2010-07-09
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd
    Full Title: A single centre, randomised, partially-blind, placebo-controlled 3 way crossover pilot study investigating efficacy in terms of heartburn relief after taking (2x250mg) Gaviscon® chewable tablets...
    Medical condition: Investigating efficacy in terms of heatburn relief in healthy subjects following a refluxogenic meal.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022082-10 Sponsor Protocol Number: ZEG/01-2010 (GERD) Start Date*: 2011-02-09
    Sponsor Name:Norgine Ltd
    Full Title: A double-blind, double-dummy, randomised, study to assess the superiority of Zegerid® 20 mg vs. Losec® 20 mg in the rapid relief of heartburn associated with GERD as on demand therapy.
    Medical condition: Heartburn associated with gastro-oesophageal reflux disease (GERD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-003174-17 Sponsor Protocol Number: GA1405 Start Date*: 2015-03-24
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited
    Full Title: A multicentre, randomised, double-blind, two arm, parallel group, placebo controlled pivotal study to assess the effect of a sodium alginate liquid suspension as add-on therapy in GORD patients wit...
    Medical condition: Gastro-Oesophageal Reflux Disease (GORD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001681-15 Sponsor Protocol Number: TAK-390MR_207 Start Date*: 2012-10-17
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd
    Full Title: A Phase 2 Multicenter, 36-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenan...
    Medical condition: Heartburn and Erosive Esophagitis in Adolescent Subjects
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10018203 GERD LLT
    14.1 10017947 - Gastrointestinal disorders 10019326 Heartburn LLT
    14.1 10017947 - Gastrointestinal disorders 10063657 Erosive esophagitis LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005821-31 Sponsor Protocol Number: GA0706 Start Date*: 2008-01-15
    Sponsor Name:Reckitt Benckiser Healthcare UK) Limited [...]
    1. Reckitt Benckiser Healthcare UK) Limited
    2. Reckitt Benckiser Healthcare (UK) Limited
    Full Title: A single-centre randomised, partially blind, single dose, crossover pilot study investigating the use of stopwatches to assess the onset of action of soothing and cooling of Gaviscon Peppermint Liq...
    Medical condition: Symptoms of heartburn
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-000257-22 Sponsor Protocol Number: D9612L00104 Start Date*: 2006-07-03
    Sponsor Name:AstraZeneca UK Ltd
    Full Title: A study to assess the effectiveness of esomeprazole 40 mg once daily in subjects with continuing gastroesophageal reflux disease (GORD) symptoms following treatment with a previous full dose proton...
    Medical condition: Gastroesophageal Reflux Disease (GORD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006413-25 Sponsor Protocol Number: GA0821 Start Date*: 2008-12-09
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited
    Full Title: A single-centre randomised, partially blind, single dose, crossover study investigating the onset of action of soothing and cooling after taking Gaviscon Peppermint liquid, Double Action Gaviscon ...
    Medical condition: Symptoms of heartburn
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001680-72 Sponsor Protocol Number: TAK-390MR_206 Start Date*: 2012-10-09
    Sponsor Name:Takeda Development Centre Europe Ltd
    Full Title: A Phase 2 Open-Label, Multicenter, 4-Week Study to Assess the safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Relief of Heartburn, in Adolescen...
    Medical condition: Heartburn in Adolescent subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004856 10066874 Gastroesophageal reflux disease LLT
    14.1 100000004856 10019326 Heartburn LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) PT (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005216-15 Sponsor Protocol Number: ABO-NB-15 Start Date*: 2016-07-06
    Sponsor Name:ABOCA S.P.A. SOCIETà AGRICOLA
    Full Title: Relief of heartburn and epigastric pain comparing Neobianacid® with omeprazole: a randomized, double blind, double dummy, reference product controlled, parallel group, non-inferiority clinical study
    Medical condition: GERD (Gastroesophageal Reflux Disease) and/or EPS (Epigastric Pain Syndrome)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10015015 Epigastric burning LLT
    20.1 100000004856 10066998 Gastroesophageal burning LLT
    20.1 100000004856 10066990 Gastrooesophageal burning LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006726-26 Sponsor Protocol Number: 101266 Start Date*: 2007-03-05
    Sponsor Name:Orexo AB
    Full Title: An open-label randomised observer-blind study to evaluate 24-hour intragastric pH profile at day 1 and day 14 during treatment with a fixed combination of a histamine type 2 receptor antagonist and...
    Medical condition: Frequent heartburn
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004174-34 Sponsor Protocol Number: Citalopram2017 Start Date*: 2018-04-10
    Sponsor Name:Targid, KU Leuven
    Full Title: A placebo-controlled trial with citalopram for the treatment of typical reflux symptoms in patients with reflux hypersensitivity or functional heartburn with incomplete proton pump inhibitor response
    Medical condition: Functional heartburn and reflux hypersensitivity with incomplete respons to proton pomp inhibitors
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002188-84 Sponsor Protocol Number: GA1203 Start Date*: 2012-07-27
    Sponsor Name:Reckitt Benckiser Healthcare (UK) LTD
    Full Title: A multi-centred, randomised, double-blind, two arm, parallel group, placebo-controlled, pilot study to assess the effect of Gaviscon Double Action Tablets in patients with reflux disease
    Medical condition: This pilot study of Gaviscon Double Action Tablets is to be conducted to demonstrate that Gaviscon Double Action Tablets are effective in managing the symptoms of heartburn, acid regurgitation and ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004470-25 Sponsor Protocol Number: GA1214 Start Date*: 2013-01-08
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd
    Full Title: A multicentre, randomised, double-blind, two arm, parallel group, pilot study to assess the effect of Gaviscon® Double Action Mint as add-on therapy in GORD patients with inadequate response to onc...
    Medical condition: Patients with Gastro Oesophageal Reflux Disease (GORD) with inadequate response to PPI treatment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001154-14 Sponsor Protocol Number: Vonoprazan-2001 Start Date*: 2016-05-23
    Sponsor Name:Takeda Development Centre Europe Ltd
    Full Title: A Randomized, Double-Blind, Proof-of-Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Once Daily Oral Vonoprazan 20 mg or Vonoprazan 40 mg Compared to Esomeprazole 40 mg for the Treatm...
    Medical condition: Gastro-Esophageal Reflux Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10017947 - Gastrointestinal disorders 10017885 Gastrooesophageal reflux disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) EE (Completed) BE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-004388-62 Sponsor Protocol Number: SPD557-206 Start Date*: 2012-04-24
    Sponsor Name:Shire-Movetis NV
    Full Title: A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate Efficacy of a Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in subjects with Gastroesoph...
    Medical condition: Gastroesophageal reflux disease (GERD) with persistent symptoms of regurgitation (with or without heartburn) while on a proton pump inhibitor therapy.
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004856 10066874 Gastroesophageal reflux disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) HU (Completed) DE (Completed) BE (Completed) LV (Completed) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 03:47:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA